Aurinia Q2 Revenue Jumps 19% to $83.2M, EPS Soars 75% to $0.28; Guidance Reiterated
AUPH sits 52% above its 52-week low of $10.34.
Summary
Aurinia delivered strong Q2 results with LUPKYNIS net product sales up 19% to $79.4M, driving total revenue to $83.2M. Net income surged 74% to $37.4M, and diluted EPS hit $0.28, a 75% increase. The company generated $52.5M in operating cash flow and ended the quarter with $443.1M in cash, after repurchasing 5M shares for $74.9M. Full-year guidance was reiterated at $315M-$325M in total revenue, signaling confidence in continued growth. The launch of the PRESERVE Phase 4 study and advancement of aritinercept into four indications highlight pipeline momentum. This follows the Kezar acquisition and positive LUPKYNIS data in June, reinforcing a strong operational trajectory.
At the time of this announcement, AUPH was trading at $15.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $10.34 to $19.25. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.